Aspen sheds R18.5bn on sale of baby milk business
The unit was sold to French dairy giant Lascalis for $860m, short of the $1bn-$1.5bn the market expected
Africa’s biggest drug manufacturer Aspen Pharmacare shed R18.5bn of its value on Thursday after the market took a dim view of the price it got for the sale of its infant milk business, and its reported earnings, which fell short of expectations. Aspen’s share price took its biggest intraday knock in two decades, plunging as much as 26% before recovering to close 14.8% lower at R232.06, leaving its market capitalisation at R105.9bn. The one-day decline dwarfs the market value of local drug maker Adcock Ingram, which is worth R11.1bn. If you are already a subscriber, please click on the following link to go to the full article: Aspen sinks on sale of baby milk business If you would like to subscribe to BusinessLIVE Premium to read the full story, please click here.
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Subscribe now to unlock this article.
Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).
There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.
Cancel anytime.
Questions? Email helpdesk@businesslive.co.za or call 0860 52 52 00. Got a subscription voucher? Redeem it now.